Enoxacin therapy for severe pleuro-pulmonary infections.
Enoxacin, a new 6-fluoroquinolone known to be active in vitro against most common pulmonary pathogens, was evaluated in comparison with ceftazidime, a third generation cephalosporin proven to be effective in the treatment of gram negative pneumonias. Clinical and microbiologic responses to therapy were satisfactory and comparable in both antibiotic groups. Enoxacin could be an effective alternative choice in the treatment of lower respiratory tract infections caused by gram negative organisms.
Thadepalli
H
H
Division of Infectious Diseases, Martin Luther King Jr General Hospital, Los Angeles.
Mathai
D
D
Bansal
M B
MB
Chuah
S K
SK
D000328:Adult; D002442:Ceftazidime / Q000627:therapeutic use*; D015365:Enoxacin / Q000627:therapeutic use*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D011446:Prospective Studies; D013183:Sputum / Q000382:microbiology
D015365:Enoxacin; D002442:Ceftazidime